Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Exact Sciences ( (EXAS) ) is now available.
On August 6, 2025, Exact Sciences announced a collaboration with Freenome Holdings to develop blood-based colorectal cancer screening products. The company reported record second-quarter revenue of $811 million, a 16% increase from the previous year, and raised its full-year revenue and adjusted EBITDA guidance. Key achievements included gaining Medicare coverage for its Oncodetect test and launching a multi-year productivity plan targeting $150 million in savings by 2026.
The most recent analyst rating on (EXAS) stock is a Buy with a $65.00 price target. To see the full list of analyst forecasts on Exact Sciences stock, see the EXAS Stock Forecast page.
Spark’s Take on EXAS Stock
According to Spark, TipRanks’ AI Analyst, EXAS is a Neutral.
Exact Sciences’ overall stock score reflects a mix of strong growth potential and significant profitability challenges. Financial performance is hampered by negative margins, while technical analysis indicates weak momentum. The earnings call provides optimism with improved profitability and successful product launches. However, valuation concerns persist due to a negative P/E ratio and absence of dividends.
To see Spark’s full report on EXAS stock, click here.
More about Exact Sciences
Exact Sciences Corp. is a leading provider in the cancer screening and diagnostic industry, primarily offering laboratory services through products like Cologuard tests and Oncotype DX. The company focuses on early cancer detection and precision oncology, aiming to improve patient outcomes through innovative diagnostic solutions.
Average Trading Volume: 2,776,903
Technical Sentiment Signal: Sell
Current Market Cap: $8.93B
See more data about EXAS stock on TipRanks’ Stock Analysis page.